Midive

Riociguat, the active ingredient in Midive, is a soluble guanylate cyclase stimulator presented as an oral tablet for oral use. It improves exercise capacity and delays disease progression in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, conditions characterized by elevated pulmonary vascular resistance.

GNH USA supplies Midive as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and quality‑assured product for the management of rare pulmonary vascular diseases.

Riociguat is indicated for pulmonary vascular diseases that involve elevated pulmonary arterial pressure.

Pulmonary arterial hypertension: improves exercise capacity and delays clinical worsening. Chronic thromboembolic pulmonary hypertension: enhances functional class and reduces pulmonary vascular resistance.

Riociguat may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache - Dizziness - Nausea

Serious or Rare Side Effects: - Severe hypotension - Pulmonary hemorrhage - Liver enzyme elevation

When prescribing Riociguat, clinicians should consider several safety aspects.

Renal impairment: monitor renal function and adjust therapy as needed. Hepatic impairment: use with caution; liver function tests should be performed regularly. Hypotension: check blood pressure before initiation and periodically during treatment. Concomitant nitrates: avoid co‑administration due to risk of additive vasodilation. Pregnancy: avoid unless the potential benefit justifies the potential risk to the fetus. Store at room temperature: keep in the original container, protect from moisture and light.

Riociguat interacts with several medicines; some combinations should be avoided while others require careful monitoring.

Major Interactions (Avoid): - Phosphodiesterase‑5 inhibitors: may cause severe hypotension. - Nitrates and nitric‑oxide donors: